Female Sexual Dysfunction Treatment Market by Age Group, Product, and Geography - Forecast and Analysis 2023-2027

Published: Nov 2022

Pages: 156

SKU: IRTNTR70409

Snapshot

Female Sexual Dysfunction Treatment Market Analysis Report 2023-2027:

The female sexual dysfunction treatment market size is estimated to grow at a CAGR of 34.28% between 2022 and 2027. The female sexual dysfunction treatment market is forecast to increase by USD 7,760.77 million. The growth of the market depends on several factors, including the increasing prevalence of chronic diseases, growing awareness of female sexual dysfunction, and approval and availability of drugs to treat hypoactive sexual desire disorder.

This market report extensively covers market segmentation by age group (above 40 years and below 40 years), product (non-hormonal therapy and hormonal therapy), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Female Sexual Dysfunction Treatment Market During the Forecast Period?

To learn more about this report, View Report Sample

Female Sexual Dysfunction Treatment Market: Key Drivers, Trends, Challenges, and Customer Landscape

The growing awareness of female sexual dysfunction is notably driving the market growth, although factors such as the adverse effects of drugs used in female sexual dysfunction treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Female Sexual Dysfunction Treatment Market Driver

Increased awareness of female sexual dysfunctions among women will drive the market's growth during the forecast period. The International Society for Sexual Medicine plays a leading role in ensuring that the latest evidence-based scientific developments in sexual medicine reach the entire target audience of both male and female sexual health practitioners and patients around the world. The organization focuses on investing in improved communications and marketing with the goal of providing more awareness, appreciation, and support for sexual medicine/health. Right to desire is a campaign for women with sexual dysfunctions. It is sponsored by Sprout Pharmaceuticals and aims to educate women regarding female sexual dysfunctions.

In addition, W2O Group, in collaboration with the American Sexual Health Association, launched an education program called Find My Spark. The program aims to encourage women to speak with their partners and health-care providers about any sexual difficulties they are facing. All such initiatives will contribute to the growth of the market during the forecast period.

Key Female Sexual Dysfunction Treatment Market Trends

Safety label changes for female sexual dysfunction therapy will accelerate market growth during the forecast period. Addyi was approved in August 2015 for the treatment of hypoactive sexual desire disorder in women. However, US FDA reviewed data that included several concerning cases of severe low blood pressure and death when flibanserin and alcohol were taken together. Therefore, in April 2019, US FDA issued a safety labelling change order to Sprout Pharmaceuticals, which needs the company to revise the safety information for Addyi. The recent labelling of Addyi includes a box stating that alcohol must be avoided in women treated with flibanserin.

Furthermore, US FDA instructed the company to take a risk evaluation and mitigation strategy for Addyi by certified healthcare professionals and pharmacies with the risk evaluation and mitigation strategy program for the product and by counselling patients about the risk of hypotension and syncope. In addition, US FDA wanted Sprout Pharmaceuticals to study further the interaction between flibanserin and alcohol after approval. Such initiatives will increase patient compliance, thereby accelerating the market's growth during the forecast period.

Key Female Sexual Dysfunction Treatment Market Challenge

The adverse effects of drugs used in female sexual dysfunction treatment are the major challenge impeding the market growth. Sexual dysfunctions in women can be treated with hormonal therapy, which includes estrogen therapy and androgen therapy, as well as drugs, such as ospemifene (Osphena) and flibanserin (Addyi). However, these treatments are associated with adverse effects. The potential adverse effects of estrogen and androgen therapy include risks of breast and ovarian cancer, stroke, pulmonary thromboembolism, and vision loss caused by a blood clot in the eye. Osphena is an estrogen agonist which is prescribed for painful intercourse. The dose of Osphena is a 60 mg tablet, which needs to be taken once daily with food. The drug can cause cardiovascular disorders and malignant neoplasms.

According to clinical trials, incidence rates of thromboembolic and hemorrhagic stroke were 0.72 per 1,000 women and 1.45 per 1,000 women, respectively. Moreover, Osphena can cause allergic conditions, including hypersensitivity, angioedema, rash, rash erythematous, generalized rash, pruritus, and urticaria. Similarly, flibanserin can cause central nervous system depression with somnolence and sedation. It can also cause hypotension and syncope. Therefore, such adverse effects associated with the treatment of sexual dysfunctions in women can decrease patient compliance, thereby leading to a decline in the market's growth during the forecast period.

Key Female Sexual Dysfunction Treatment Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Female Sexual Dysfunction Treatment Market Customer Landscape

Who are the Major Female Sexual Dysfunction Treatment Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Pfizer - The company offers female sexual dysfunction treatment such as questionnaires and screeners. The company is engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide.

The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Female Sexual Dysfunction Treatment Market?

Based on age group, the market is segmented into above 40 years and below 40 years. The market share growth of the above 40 years segment will be significant during the forecast period. The above 40 years segment in the global female sexual dysfunction treatment market is expected to witness significant growth during the forecast period. This is due to the rising number of incidents of CVDs, diabetes, and cancer among the above 40 years age group. The prevalence of chronic diseases in the segment is expected to increase the patient pool and hence the segment growth during the forecast period.

Get a glance at the market contribution of various segments View PDF Sample

The above 40 years segment was valued at USD 422.63 million in 2017 and continued to grow until 2021. The prevalence of cardiovascular diseases (CVDs) was high in many countries like India. Approximately 4.77 million were diagnosed as positive, with 20.2% diabetes, 53.7% hypertension, 77% overweight/obesity, and 92% central obesity in 2020. Similarly, in the UK, around 7600 women above 40 years were diagnosed with breast cancer in 2020. Such factors are anticipated to drive the demand for female sexual dysfunction treatment in the above 40 years segment, which is expected to fuel the growth of the market during the forecast period.

Which are the Key Regions for the Female Sexual Dysfunction Treatment Market?

For more insights on the market share of various regions View PDF Sample now!

North America is projected to account for 61% of the global market share growth by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The female sexual dysfunction treatment market in North America is led by the US. According to the data published by the CDC in 2020, nearly 9.5% of women in the US were diagnosed with diabetes during 2017-2018. The prevalence of breast cancer in the US was found to be 128.3 per 100,000 women. Therefore, the rising prevalence of chronic diseases will increase the risk and incidence of sexual dysfunction in women, which will drive market growth in the region during the forecast period. In addition, according to the data provided by the Blue Cross Blue Shield Association, a federation of 36 separate US health insurance companies, nearly 43% of American women were estimated to experience female sexual dysfunction to some degree every year across the US. An expected rise in the incidence of sexual dysfunction among women is expected to boost the demand for treatment, which in turn, is also expected to increase the growth opportunities in the market in North America during the forecast period.

In 2020, the outbreak of COVID-19 had a negative impact on the regional market. However, in 2021, due to the availability of vaccines, the number of COVID-19 cases declined in the region. Owing to the ease of COVID-19-related restrictions and with access to hospitals and clinics being restored, the demand for female sexual dysfunction treatment drugs rebounded in 2021. Thus, owing to these factors, the regional market is expected to witness growth during the forecast period.

Segment Overview

The female sexual dysfunction treatment market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Age Group Outlook (USD Million, 2017 - 2027)
- Above 40 years
- Below 40 years

Product Outlook (USD Million, 2017 - 2027)
- Non-hormonal therapy
- Hormonal therapy

Region Outlook (USD Million, 2017 - 2027)
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- APAC
  - China
  - India
  - Singapore
- Rest of World (ROW)
  - Brazil
  - Argentina
  - Rest of the Middle East & Africa

Female Sexual Dysfunction Treatment Market Scope
Report Coverage	Details
Page number	156
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 34.28%
Market growth 2023-2027	USD 7,760.77 million
Market structure	Fragmented
YoY growth (%)	32.7
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 61%
Key countries	US, Canada, Germany, UK, and France
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Assos Ilac, Cipla Ltd., Dare Bioscience Inc., Dr Reddys Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Get access to Report Sample PDF !

What are the Key Data Covered in this Female Sexual Dysfunction Treatment Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the sexual dysfunction treatment market between 2023 and 2027
Precise estimation of the female sexual dysfunction treatment market size and its contribution of the market in focus to the parent market
Accurate predictions about upcoming trends and changes in consumer behaviour
Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of female sexual dysfunction treatment market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Age Group
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global female sexual dysfunction treatment market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global female sexual dysfunction treatment market 2017 - 2021 ($ million)

4.2 Age Group Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Age Group Segment 2017 - 2021 ($ million)

4.3 Product Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Age Group

6.1 Market segments
- Exhibit 30: Chart on Age Group - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Age Group - Market share 2022-2027 (%)

6.2 Comparison by Age Group
- Exhibit 32: Chart on Comparison by Age Group
- Exhibit 33: Data Table on Comparison by Age Group

6.3 Above 40 years - Market size and forecast 2022-2027
- Exhibit 34: Chart on Above 40 years - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Above 40 years - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Above 40 years - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Above 40 years - Year-over-year growth 2022-2027 (%)

6.4 Below 40 years - Market size and forecast 2022-2027
- Exhibit 38: Chart on Below 40 years - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Below 40 years - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Below 40 years - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Below 40 years - Year-over-year growth 2022-2027 (%)

6.5 Market opportunity by Age Group
- Exhibit 42: Market opportunity by Age Group ($ million)

7 Market Segmentation by Product

7.1 Market segments
- Exhibit 43: Chart on Product - Market share 2022-2027 (%)
- Exhibit 44: Data Table on Product - Market share 2022-2027 (%)

7.2 Comparison by Product
- Exhibit 45: Chart on Comparison by Product
- Exhibit 46: Data Table on Comparison by Product

7.3 Non-hormonal therapy - Market size and forecast 2022-2027
- Exhibit 47: Chart on Non-hormonal therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Data Table on Non-hormonal therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Chart on Non-hormonal therapy - Year-over-year growth 2022-2027 (%)
- Exhibit 50: Data Table on Non-hormonal therapy - Year-over-year growth 2022-2027 (%)

7.4 Hormonal therapy - Market size and forecast 2022-2027
- Exhibit 51: Chart on Hormonal therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 52: Data Table on Hormonal therapy - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Chart on Hormonal therapy - Year-over-year growth 2022-2027 (%)
- Exhibit 54: Data Table on Hormonal therapy - Year-over-year growth 2022-2027 (%)

7.5 Market opportunity by Product
- Exhibit 55: Market opportunity by Product ($ million)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 57: Chart on Market share by geography 2022-2027 (%)
- Exhibit 58: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 59: Chart on Geographic comparison
- Exhibit 60: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027
- Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027
- Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027
- Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 Canada - Market size and forecast 2022-2027
- Exhibit 81: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 82: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 83: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on Canada - Year-over-year growth 2022-2027 (%)

9.9 Germany - Market size and forecast 2022-2027
- Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.10 UK - Market size and forecast 2022-2027
- Exhibit 89: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 90: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 91: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.11 France - Market size and forecast 2022-2027
- Exhibit 93: Chart on France - Market size and forecast 2022-2027 ($ million)
- Exhibit 94: Data Table on France - Market size and forecast 2022-2027 ($ million)
- Exhibit 95: Chart on France - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on France - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 97: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 98: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 99: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 100: Overview on factors of disruption

11.4 Industry risks
- Exhibit 101: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 102: Vendors covered

12.2 Market positioning of vendors
- Exhibit 103: Matrix on vendor position and classification

12.3 Cipla Ltd.
- Exhibit 104: Cipla Ltd. - Overview
- Exhibit 105: Cipla Ltd. - Business segments
- Exhibit 106: Cipla Ltd. - Key news
- Exhibit 107: Cipla Ltd. - Key offerings
- Exhibit 108: Cipla Ltd. - Segment focus

12.4 Dare Bioscience Inc.
- Exhibit 109: Dare Bioscience Inc. - Overview
- Exhibit 110: Dare Bioscience Inc. - Product / Service
- Exhibit 111: Dare Bioscience Inc. - Key offerings

12.5 Dr Reddys Laboratories Ltd.
- Exhibit 112: Dr Reddys Laboratories Ltd. - Overview
- Exhibit 113: Dr Reddys Laboratories Ltd. - Business segments
- Exhibit 114: Dr Reddys Laboratories Ltd. - Key offerings
- Exhibit 115: Dr Reddys Laboratories Ltd. - Segment focus

12.6 Duchesnay Inc.
- Exhibit 116: Duchesnay Inc. - Overview
- Exhibit 117: Duchesnay Inc. - Product / Service
- Exhibit 118: Duchesnay Inc. - Key offerings

12.7 Endo International Plc
- Exhibit 119: Endo International Plc - Overview
- Exhibit 120: Endo International Plc - Business segments
- Exhibit 121: Endo International Plc - Key news
- Exhibit 122: Endo International Plc - Key offerings
- Exhibit 123: Endo International Plc - Segment focus

12.8 Freya Pharma Solutions B.V.
- Exhibit 124: Freya Pharma Solutions B.V. - Overview
- Exhibit 125: Freya Pharma Solutions B.V. - Product / Service
- Exhibit 126: Freya Pharma Solutions B.V. - Key offerings

12.9 Lupin Ltd.
- Exhibit 127: Lupin Ltd. - Overview
- Exhibit 128: Lupin Ltd. - Product / Service
- Exhibit 129: Lupin Ltd. - Key news
- Exhibit 130: Lupin Ltd. - Key offerings

12.10 Mithra Pharmaceuticals SA
- Exhibit 131: Mithra Pharmaceuticals SA - Overview
- Exhibit 132: Mithra Pharmaceuticals SA - Product / Service
- Exhibit 133: Mithra Pharmaceuticals SA - Key offerings

12.11 Novo Nordisk AS
- Exhibit 134: Novo Nordisk AS - Overview
- Exhibit 135: Novo Nordisk AS - Business segments
- Exhibit 136: Novo Nordisk AS - Key offerings
- Exhibit 137: Novo Nordisk AS - Segment focus

12.12 Palatin Technologies Inc.
- Exhibit 138: Palatin Technologies Inc. - Overview
- Exhibit 139: Palatin Technologies Inc. - Product / Service
- Exhibit 140: Palatin Technologies Inc. - Key offerings

12.13 Pfizer Inc.
- Exhibit 141: Pfizer Inc. - Overview
- Exhibit 142: Pfizer Inc. - Product / Service
- Exhibit 143: Pfizer Inc. - Key news
- Exhibit 144: Pfizer Inc. - Key offerings

12.14 Sprout Pharmaceuticals Inc.
- Exhibit 145: Sprout Pharmaceuticals Inc. - Overview
- Exhibit 146: Sprout Pharmaceuticals Inc. - Product / Service
- Exhibit 147: Sprout Pharmaceuticals Inc. - Key offerings

12.15 Strategic Science and Technologies LLC
- Exhibit 148: Strategic Science and Technologies LLC - Overview
- Exhibit 149: Strategic Science and Technologies LLC - Product / Service
- Exhibit 150: Strategic Science and Technologies LLC - Key offerings

12.16 Teva Pharmaceutical Industries Ltd.
- Exhibit 151: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 152: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 153: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 154: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 155: Teva Pharmaceutical Industries Ltd. - Segment focus

12.17 Viatris Inc.
- Exhibit 156: Viatris Inc. - Overview
- Exhibit 157: Viatris Inc. - Business segments
- Exhibit 158: Viatris Inc. - Key offerings
- Exhibit 159: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 160: Inclusions checklist
- Exhibit 161: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 162: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 163: Research methodology
- Exhibit 164: Validation techniques employed for market sizing
- Exhibit 165: Information sources

13.5 List of abbreviations
- Exhibit 166: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

female sexual dysfunction treatment market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis